About Presidio Pharmaceuticals
Presidio Pharmaceuticals is a company based in San Francisco (United States) founded in 2006 by Omar Haffar. Presidio Pharmaceuticals has raised $91.93 million across 7 funding rounds from investors including New Leaf Venture Partners, Panorama Capital and Bay City Capital. Presidio Pharmaceuticals operates in a competitive market with competitors including NGM Biopharmaceuticals, Prenetics, Nimbus Therapeutics, OpGen and Altimmune, among others.
- Headquarter San Francisco, United States
- Founders Omar Haffar
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$91.93 M (USD)
in 7 rounds
-
Latest Funding Round
$21.83 M (USD), Series C
Jun 13, 2014
-
Investors
New Leaf Venture Partners
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Presidio Pharmaceuticals
Presidio Pharmaceuticals has successfully raised a total of $91.93M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $21.83 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Presidio Pharmaceuticals
Presidio Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Panorama Capital and Bay City Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Early & later stage venture capital firm investing in the US
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Locked | Locked | Locked |
Investor details for Presidio Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Presidio Pharmaceuticals
Investment portfolio details for Presidio Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Presidio Pharmaceuticals
Detailed financials for Presidio Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Presidio Pharmaceuticals Comparisons
Peer comparison for Presidio Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Presidio Pharmaceuticals
Presidio Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Prenetics, Nimbus Therapeutics, OpGen and Altimmune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
Detailed competitors of Presidio Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Presidio Pharmaceuticals
Complete news archive for Presidio Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Presidio Pharmaceuticals
Presidio Pharmaceuticals was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Presidio Pharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Presidio Pharmaceuticals is a funded company, having raised a total of $91.93M across 7 funding rounds to date.
Presidio Pharmaceuticals was founded in 2006 in San Francisco, United States, within the biopharmaceutical sector. Small-molecule antiviral therapeutics are developed, focusing on treatments for hepatitis C virus infections. The lead candidate, ravidasvir hydrochloride, is advanced for use in both healthy volunteers and patients, with antiviral activity observed in clinical evaluations. Operations center on therapeutic innovation for viral diseases.
Presidio Pharmaceuticals's top competitors include Nimbus Therapeutics, Prenetics and NGM Biopharmaceuticals.
Presidio Pharmaceuticals has 5 investors. Key investors include New Leaf Venture Partners, Panorama Capital, Bay City Capital, Ventures West, and Nexus Medical Partners.